Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 34Unknown 22Completed 15Not yet recruiting 11Active not recruiting 10Terminated 8Approved for marketing 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 438Triple Negative Breast Neoplasms 50Neoplasm Metastasis 24Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 22Colorectal Neoplasms 18Carcinoma, Intraductal, Noninfiltrating 18Neoplasms 16Pancreatic Neoplasms 14Prostatic Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 12Colonic Neoplasms 11Breast Neoplasms, Male 10Urinary Bladder Neoplasms 8Small Cell Lung Carcinoma 8Melanoma 8Fatigue 8Breast Carcinoma In Situ 8Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lymphedema 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Cancer Female 6Testicular Neoplasms 5Pain 5Esophageal Neoplasms 5

Interventions

pertuzumab 1Trastuzumab 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × HER2-positive Breast Cancer × Breast × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡